The efficacy of dupilumab as an adjuvant treatment after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: a retrospective cohort analysis.
Chin-Nung Liu, Te-Huei Yeh, Chih-Feng Lin, Yi-Tsen Lin
{"title":"The efficacy of dupilumab as an adjuvant treatment after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: a retrospective cohort analysis.","authors":"Chin-Nung Liu, Te-Huei Yeh, Chih-Feng Lin, Yi-Tsen Lin","doi":"10.21053/ceo.2024.00310","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high recurrence rate following endoscopic sinus surgery (ESS). The role of adjunctive biologic therapy remains to be fully elucidated. This study aims to assess the efficacy of dupilumab in conjunction with ESS for patients with CRSwNP.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of type 2 CRSwNP patients who underwent ESS. The study compared those who received postoperative dupilumab to those who underwent standard care. Changes in the Lund-Kennedy endoscopic score (LKES) and nasal polyp score (NPS) were recorded, and linear mixed models (LMMs) were utilized for primary outcome analysis.</p><p><strong>Results: </strong>The study enrolled 49 CRSwNP patients, with 22 patients in the dupilumab group. Postoperative LKES and NPS decreased in both groups. LMM showed significant improvement in LKESs (B = -0.61, 95% CI: -0.90 to -0.31, P < 0.001) and more pronounced improvement in NPSs (B = -0.14, 95% CI: -0.25 to -0.02, P = 0.025) in the dupilumab group from pre- to post-operation measurements compared to control group.</p><p><strong>Conclusion: </strong>In comparison to ESS alone, the adjunctive use of dupilumab in the postoperative period was associated with greater reductions in both nasal polyp scores and endoscopic scores.</p>","PeriodicalId":10318,"journal":{"name":"Clinical and Experimental Otorhinolaryngology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21053/ceo.2024.00310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high recurrence rate following endoscopic sinus surgery (ESS). The role of adjunctive biologic therapy remains to be fully elucidated. This study aims to assess the efficacy of dupilumab in conjunction with ESS for patients with CRSwNP.
Methods: We conducted a retrospective cohort study of type 2 CRSwNP patients who underwent ESS. The study compared those who received postoperative dupilumab to those who underwent standard care. Changes in the Lund-Kennedy endoscopic score (LKES) and nasal polyp score (NPS) were recorded, and linear mixed models (LMMs) were utilized for primary outcome analysis.
Results: The study enrolled 49 CRSwNP patients, with 22 patients in the dupilumab group. Postoperative LKES and NPS decreased in both groups. LMM showed significant improvement in LKESs (B = -0.61, 95% CI: -0.90 to -0.31, P < 0.001) and more pronounced improvement in NPSs (B = -0.14, 95% CI: -0.25 to -0.02, P = 0.025) in the dupilumab group from pre- to post-operation measurements compared to control group.
Conclusion: In comparison to ESS alone, the adjunctive use of dupilumab in the postoperative period was associated with greater reductions in both nasal polyp scores and endoscopic scores.
期刊介绍：
Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an international peer-reviewed journal on recent developments in diagnosis and treatment of otorhinolaryngology-head and neck surgery and dedicated to the advancement of patient care in ear, nose, throat, head, and neck disorders. This journal publishes original articles relating to both clinical and basic researches, reviews, and clinical trials, encompassing the whole topics of otorhinolaryngology-head and neck surgery.
CEO was first issued in 2008 and this journal is published in English four times (the last day of February, May, August, and November) per year by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. The Journal aims at publishing evidence-based, scientifically written articles from different disciplines of otorhinolaryngology field.
The readership contains clinical/basic research into current practice in otorhinolaryngology, audiology, speech pathology, head and neck oncology, plastic and reconstructive surgery. The readers are otolaryngologists, head and neck surgeons and oncologists, audiologists, and speech pathologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
